Anzeige
❌
Mehr »
Login
Dienstag, 08.04.2025 Börsentäglich über 12.000 News von 689 internationalen Medien
Deutsche Rohstoff AG Gründer Dr. Gutschlag über Highflyer Almonty Industries Inc.
Anzeige

Indizes
Kurs
%		News
24 h / 7 T		Aufrufe
7 Tage

Aktien
Kurs
%		News
24 h / 7 T		Aufrufe
7 Tage

Xetra-Orderbuch

Fonds
Kurs
%

Devisen
Kurs
%

Rohstoffe
Kurs
%

Themen
Kurs
%

Erweiterte Suche

WKN: A3CMJ9 | ISIN: US16385C1045 | Ticker-Symbol: 2QV0
Tradegate
07.04.25
11:43 Uhr
0,925 Euro
-0,035
-3,65 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
CHEMOMAB THERAPEUTICS LTD ADR Chart 1 Jahr
5-Tage-Chart
CHEMOMAB THERAPEUTICS LTD ADR 5-Tage-Chart
RealtimeGeldBriefZeit
0,9150,96507.04.

Aktuelle News zur CHEMOMAB THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrChemomab Therapeutics Ltd. - 20-F, Annual and transition report of foreign private issuers1SEC Filings
27.03.Chemomab Therapeutics' Touts Positive Data From Experimental Drug For Chronic Liver Disease1Benzinga.com
27.03.Chemomab Therapeutics: Chemomab Reports Positive Results in Nebokitug Phase 2 PSC Open Label Extension Trial Showing Continued Broad and Substantial Improvements in Key Liver Biomarkers103GlobeNewswire (Europe)Reinforces potential of nebokitug to become the first approved drug with disease-modifying activity for PSC--a deadly disorder that currently has no effective treatments Treatment in PSC patients...
► Artikel lesen
20.03.Chemomab Therapeutics Ltd. - 6-K, Report of foreign issuer2SEC Filings
03.03.Chemomab Therapeutics GAAP EPS of -$0.011Seeking Alpha
03.03.Chemomab Therapeutics Ltd. Q4 Loss Decreases2RTTNews
CHEMOMAB THERAPEUTICS Aktie jetzt für 0€ handeln
03.03.Chemomab Therapeutics Announces Year End and Fourth Quarter 2024 Financial Results and Provides a Corporate Update138GlobeNewswire (Europe)-Completed Successful FDA End-of-Phase 2 Meeting Following Positive Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis (PSC)- -Achieved Alignment with FDA on Clear and Efficient...
► Artikel lesen
03.03.Chemomab Therapeutics Ltd. - 6-K, Report of foreign issuer-SEC Filings
19.02.Chemomab Therapeutics: Chemomab Completes Successful End-of-Phase 2 Meeting and Aligns with FDA on Clear and Efficient Path to Potential Regulatory Approval for Nebokitug (CM-101) in Primary Sclerosing Cholangitis87GlobeNewswire (Europe)Single Positive Phase 3 Trial Designed to Support Full Regulatory Approval, For the First Time Providing Regulatory Clarity in PSC and Positioning Nebokitug to Potentially Become the First FDA-Approved...
► Artikel lesen
19.02.Chemomab Therapeutics Ltd. - 6-K, Report of foreign issuer-SEC Filings
03.12.24Chemomab Therapeutics: Chemomab to Participate in Oppenheimer's Movers in Rare Disease Summit11GlobeNewswire (USA)
19.11.24Chemomab Therapeutics: Oral Presentation at AASLD The Liver Meeting 2024 Highlights Broad Clinical Activity of Chemomab's CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing Cholangitis6GlobeNewswire (USA)
14.11.24Chemomab Therapeutics GAAP EPS of -$0.01 beats by $0.059Seeking Alpha
14.11.24Chemomab Therapeutics Ltd. - 6-K, Report of foreign issuer-SEC Filings
11.10.24Chemomab Therapeutics Ltd. - 6-K, Report of foreign issuer1SEC Filings
21.08.24Chemomab Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update161GlobeNewswire (Europe)--Reported Positive Phase 2 Results Demonstrating Safety and Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Activity across Multiple Components of Primary Sclerosing Cholangitis (PSC)-- --Establishes...
► Artikel lesen
26.07.24Chemomab Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement126GlobeNewswire (Europe)TEL AVIV, Israel, July 26, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab) a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory...
► Artikel lesen
25.07.24Chemomab Therapeutics Announces Positive Phase 2 Trial Results: CM-101 Achieves Primary and Secondary Endpoints Demonstrating Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects in Patients with Primary Sclerosing Cholangitis135GlobeNewswire (Europe)First-in-Class CCL24 Neutralizing Antibody CM-101 Demonstrated a Favorable Safety Profile and Was Generally Well-Tolerated Demonstrated Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Activity...
► Artikel lesen
18.06.24Chemomab Therapeutics Announces New Publications Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis155GlobeNewswire (Europe)-Proteomic Analysis of Patient Samples Further Confirms that CCL24 is Associated with Primary Sclerosing Cholangitis (PSC) Severity and Progression, Highlighting the Potential of Chemomab's CCL24-Neutralizing...
► Artikel lesen
18.04.24Chemomab Therapeutics: Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis180GlobeNewswire (Europe)-Longitudinal Study of a 200+ Real-World Patient Cohort Further Validates CCL24 as a Novel Target for Systemic Sclerosis (SSc), Showing that It is Associated with Disease Severity Across the Fibrotic...
► Artikel lesen
20 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1